Loading
Life sciences · Journal article
Journal of Medicinal Chemistry · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Theranostic agents integrate diagnostic and therapeutic capabilities into a single molecular platform, offering an advanced approach to personalized medicine. The neuropeptide Y1 receptor (Y1R) is a promising target for breast cancer theranostics given its overexpression across multiple disease stages. Building on the Y1R-selective antagonist [Lys2, Arg4]BVD-15, we report the systematic development of stabilized nonapeptide analogues through strategic modifications. Lead candidates were radiolabeled in >95% radiochemical purity and showed Y1R binding affinities up to 60-fold higher than the parent peptide, no detectable plasma degradation over 90 min, and half-lives of 42−55 min in liver and kidney homogenates. PET-CT imaging in HEK-Y1R and MCF-7 tumor models demonstrated selective tumor uptake, peaking at 19.2% ID/g in HEK-Y1R tumors, with biodistribution studies confirming specific tumor accumulation and progressive clearance over 48 h. Therapeutic evaluation of lead candidate [177Lu]Lu-31 in HEK-Y1R tumor-bearing mice showed dose-dependent tumor growth inhibition, supporting this peptide class as Y1R-targeted radionuclide therapeutics.